NFL Biosciences
Develops botanical drug candidates to treat smoking and alcohol addictions.
ALNFL | PA
Overview
Corporate Details
- ISIN(s):
- FR0014003XO1 (+1 more)
- LEI:
- 9695006VJWNTN4UNHA27
- Country:
- France
- Address:
- 199 RUE HELENE BOUCHER, 34170 CASTELNAU-LE-LEZ
- Website:
- https://www.nflbiosciences.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead asset is NFL-101, an innovative drug candidate for smoking cessation derived from a nicotine-free protein extract of tobacco leaves. Its pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences operates with an outsourced research model, focusing on advancing its products through preclinical and clinical studies. The company's primary business strategy is to license its developed drug candidates to larger pharmaceutical companies for final commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-07-05 19:00 |
NFL BIOSCIENCES : RENFORCEMENT D’UN ACTIONNAIRE FONDATEUR PAR EXERCICE DE BSPCE
|
French | 423.0 KB | ||
| 2023-07-05 19:00 |
NFL BIOSCIENCES: CO-FOUNDER SHAREHOLDER FURTHER STRENGTHENS HIS POSITION BY EXE…
|
English | 354.7 KB | ||
| 2023-06-29 17:45 |
NFL BIOSCIENCES : MONTÉE AU CAPITAL DE GB HOLDING PAR EXERCICE DE BSA POUR 0,5 …
|
French | 457.6 KB | ||
| 2023-06-29 17:45 |
NFL BIOSCIENCES: GB HOLDING TAKES A STAKE IN THE COMPANY’S CAPITAL UPON THE EXE…
|
English | 386.0 KB | ||
| 2023-06-28 17:45 |
NFL BIOSCIENCES : COMPTE RENDU DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 27 JUIN 2023
|
French | 217.5 KB | ||
| 2023-06-28 17:45 |
NFL BIOSCIENCES : RESULTS OF THE COMBINED GENERAL MEETING OF JUNE 27, 2023
|
English | 193.3 KB | ||
| 2023-06-21 18:15 |
NFL BIOSCIENCES : Accord de délivrance de son brevet sur NFL-101 en Europe et v…
|
French | 78.2 KB | ||
| 2023-06-21 18:15 |
NFL BIOSCIENCES: Approval for its patent to be granted on NFL-101 in Europe and…
|
English | 70.8 KB | ||
| 2023-06-09 17:45 |
NFL Biosciences : Modalités de mise à disposition et consultation des documents…
|
French | 214.1 KB | ||
| 2023-05-09 17:45 |
NFL Biosciences : Finalisation des recrutements de l’étude PRECESTO
|
French | 131.2 KB | ||
| 2023-05-09 17:45 |
NFL Biosciences: Recruitment completed for the PRECESTO study
|
English | 129.1 KB | ||
| 2023-04-28 17:45 |
NFL Biosciences : Mise à disposition du Rapport Annuel au 31/12/2022
|
French | 106.7 KB | ||
| 2023-04-25 08:00 |
NFL Biosciences : Activités & Résultats annuels 2022
|
French | 191.7 KB | ||
| 2023-04-25 08:00 |
NFL Biosciences: 2022 full-year business and earnings update
|
English | 181.3 KB | ||
| 2023-02-27 17:45 |
Évolution de la gouvernance de NFL Biosciences
|
French | 124.0 KB |
Automate Your Workflow. Get a real-time feed of all NFL Biosciences filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NFL Biosciences
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NFL Biosciences via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
